Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) had its target price hoisted by stock analysts at Ascendiant Capital Markets from $7.00 to $7.50 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a "buy" rating on the stock. Ascendiant Capital Markets' price objective points to a potential upside of 463.91% from the stock's current price.
Several other equities analysts have also issued reports on LUCD. Needham & Company LLC restated a "buy" rating and set a $3.00 price target on shares of Lucid Diagnostics in a research report on Friday, April 11th. Cantor Fitzgerald restated an "overweight" rating and issued a $2.00 target price on shares of Lucid Diagnostics in a report on Wednesday, March 26th. Finally, BTIG Research set a $2.00 price target on shares of Lucid Diagnostics in a report on Tuesday, March 25th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Lucid Diagnostics currently has a consensus rating of "Buy" and an average price target of $3.50.
Check Out Our Latest Stock Analysis on LUCD
Lucid Diagnostics Price Performance
Shares of NASDAQ:LUCD remained flat at $1.33 on Monday. The stock had a trading volume of 1,290,521 shares, compared to its average volume of 462,467. The stock has a market capitalization of $120.70 million, a PE ratio of -1.17 and a beta of 1.26. The business has a 50 day simple moving average of $1.41 and a 200-day simple moving average of $1.09. Lucid Diagnostics has a 52-week low of $0.63 and a 52-week high of $1.80.
Hedge Funds Weigh In On Lucid Diagnostics
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. XML Financial LLC purchased a new position in Lucid Diagnostics during the 1st quarter valued at $266,000. Sunbelt Securities Inc. bought a new stake in shares of Lucid Diagnostics during the 4th quarter valued at about $67,000. Citadel Advisors LLC purchased a new position in shares of Lucid Diagnostics during the fourth quarter valued at about $98,000. Lido Advisors LLC raised its stake in Lucid Diagnostics by 40.0% in the fourth quarter. Lido Advisors LLC now owns 140,016 shares of the company's stock worth $115,000 after buying an additional 40,000 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Lucid Diagnostics by 30.9% in the fourth quarter. Geode Capital Management LLC now owns 279,504 shares of the company's stock worth $229,000 after buying an additional 65,964 shares during the period. Institutional investors own 74.01% of the company's stock.
About Lucid Diagnostics
(
Get Free Report)
Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
Featured Articles
Before you consider Lucid Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lucid Diagnostics wasn't on the list.
While Lucid Diagnostics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
